Kallikrein-related serine proteases as therapeutic targets for cancer

激肽释放酶相关丝氨酸蛋白酶作为癌症治疗靶点

• 批准号: 355696-2007
• 负责人: Diamandis, Eleftherios
• 金额: $ 7.29万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=459517
• 关键词: Kallikrein; related; serine; proteases; therapeutic

Aberrant proteolysis is associated with many diseases, including cancer. Already, many Pharmaceutical companies are targeting proteases for developing new therapeutics for cancer and other diseases. Our laboratory is leading research related to a family of serine proteases called "human tissue kallikreins" (KLKs). These KLKs are 15 extracellular proteases which appear to be closely linked to tumour progression. We thus believe that KLKs represent a new, and promising, cancer drug target. In this application, we propose to pre-clinically validate a few members of the kallikrein family as therapeutic targets for treatment of cancer. We will use quantitative proteomics, in-vitro cell-based assays and animal xenograft models to increase our understanding of kallikrein pathophysiology in breast cancer. This investigation may lead to development of novel therapies for breast and other cancers.

异常蛋白水解与许多疾病有关，包括癌症。许多制药公司已经瞄准蛋白酶来开发癌症和其他疾病的新疗法。我们的实验室正在领导与丝氨酸蛋白酶家族相关的研究，该家族被称为“人类组织激肽释放酶”（KLK）。这些KLK是15种细胞外蛋白酶，似乎与肿瘤进展密切相关。因此，我们认为KLK代表了一个新的，有前途的癌症药物靶点。在本申请中，我们提出临床前验证激肽释放酶家族的一些成员作为治疗癌症的治疗靶标。我们将使用定量蛋白质组学，体外细胞为基础的分析和动物异种移植模型，以增加我们的乳腺癌激肽释放酶的病理生理学的理解。这项研究可能会导致乳腺癌和其他癌症的新疗法的发展。